{"id":"W4408979538","doi":"10.1016/s1556-0864(25)00317-x","title":"122TiP: TROPION-Lung10: Phase III study of datopotamab deruxtecan (Dato-DXd) + rilvegostomig in non-squamous (NSQ) advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations (AGAs)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada); BC Cancer Agency","funders":"Innovent Biologics; Novocure; Regeneron Pharmaceuticals; Yuhan; Gilead Sciences; EQRx; BeiGene; Mirati Therapeutics; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Cancer research; Lung cancer; Internal medicine; non-small cell lung cancer (NSCLC); A549 cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008109779,0.00132472,0.001297179,0.0004216346,0.000302073,0.001350438,0.00103343,0.001062853,0.007876341],"category_scores_gemma":[0.0003650733,0.0004798435,0.001254804,0.0003983325,0.0006524144,0.0005471269,0.0004134572,0.003050725,0.002422925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001057834,"about_ca_system_score_gemma":0.001318433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002207702,"about_ca_topic_score_gemma":0.005835115,"domain_scores_codex":[0.9997254,0.00009375057,0.00001110028,0.00004452818,0.00002976384,0.00009539472],"domain_scores_gemma":[0.9997432,0.00002622291,0.00003286076,0.00002342952,0.00001590127,0.000158378],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3393879,0.06766156,0.01311124,0.002847212,0.003141939,0.0007496037,0.0005054289,0.01091341,0.1626224,0.001825543,0.02798535,0.3692485],"study_design_scores_gemma":[0.4672237,0.4761701,0.01726726,0.0001696401,0.001035501,0.001377257,0.0001558445,0.003325715,0.0142018,0.0004425731,0.01854185,0.00008883648],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9744394,0.005863144,0.001106357,0.001231733,0.0003710437,0.003072976,0.005713247,0.0005659729,0.00763609],"genre_scores_gemma":[0.9612314,0.005761615,0.002421343,0.001843087,0.0001486566,0.00265556,0.01221039,0.0001221429,0.01360583],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007876341,"threshold_uncertainty_score":0.02634895,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01106926510883307,"score_gpt":0.4012138063917119,"score_spread":0.3901445412828788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}